OPN 5667
Alternative Names: OPN-5667Latest Information Update: 09 Jan 2026
At a glance
- Originator Opna Bio
- Class Antineoplastics
- Mechanism of Action CREB-binding protein degraders; EP300 protein degraders; IKZF1 protein degraders; IKZF3 protein degraders
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Multiple myeloma
Most Recent Events
- 08 Dec 2025 Preclinical trials in Multiple myeloma in Switzerland (unspecified route) prior to December 2025
- 08 Dec 2025 Pharmacodynamics data from a preclinical study in Multiple myeloma released by Opna Bio
- 20 Sep 2022 Opna Bio has patent protection for "Compounds and methods for EP300 or CBP modulation and indications therefor" in the US, Australia, Japan, China and has patent pending in the European Union, Mexico, Singapore, Taiwan, Canada and Israel